A Scalable Two-Step Workflow Combining Digital Cognitive Assessment and Plasma pTau217 for Mild Cognitive Impairment Detection

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.